Literature DB >> 26704615

Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection.

Hannah E Clapham1, Isabel Rodriguez-Barraquer1, Andrew S Azman1, Benjamin M Althouse2, Henrik Salje1, Robert V Gibbons3, Alan L Rothman4, Richard G Jarman5, Ananda Nisalak5, Butsaya Thaisomboonsuk5, Siripen Kalayanarooj6, Suchitra Nimmannitya6, David W Vaughn5, Sharone Green7, In-Kyu Yoon8, Derek A T Cummings9.   

Abstract

The immune response to dengue virus (DENV) infection is complex and not fully understood. Using longitudinal data from 181 children with dengue in Thailand who were followed for up to 3 years, we describe neutralizing antibody kinetics following symptomatic DENV infection. We observed that antibody titers varied by serotype, homotypic vs heterotypic responses, and primary versus postprimary infections. The rates of change in antibody titers over time varied between primary and postprimary responses. For primary infections, titers increased from convalescence to 6 months. By comparing homotypic and heterotypic antibody titers, we saw an increase in type specificity from convalescence to 6 months for primary DENV3 infections but not primary DENV1 infections. In postprimary cases, there was a decrease in titers from convalescence up until 6 months after infection. Beginning 1 year after both primary and postprimary infections, there was evidence of increasing antibody titers, with greater increases in children with lower titers, suggesting that antibody titers were boosted due to infection and that higher levels of neutralizing antibody may be more likely to confer a sterilizing immune response. These findings may help to model virus transmission dynamics and provide baseline data to support the development of vaccines and therapeutics.
© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  dengue; longitudinal antibody kinetics; neutralizing antibody; vaccine

Mesh:

Substances:

Year:  2015        PMID: 26704615      PMCID: PMC4813744          DOI: 10.1093/infdis/jiv759

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Research on dengue during World War II.

Authors:  A B SABIN
Journal:  Am J Trop Med Hyg       Date:  1952-01       Impact factor: 2.345

Review 2.  Review article: Research on dengue during World War II revisited.

Authors:  Grace E Snow; Benjamin Haaland; Eng Eong Ooi; Duane J Gubler
Journal:  Am J Trop Med Hyg       Date:  2014-10-13       Impact factor: 2.345

3.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

Authors:  Arunee Sabchareon; Derek Wallace; Chukiat Sirivichayakul; Kriengsak Limkittikul; Pornthep Chanthavanich; Saravudh Suvannadabba; Vithaya Jiwariyavej; Wut Dulyachai; Krisana Pengsaa; T Anh Wartel; Annick Moureau; Melanie Saville; Alain Bouckenooghe; Simonetta Viviani; Nadia G Tornieporth; Jean Lang
Journal:  Lancet       Date:  2012-09-11       Impact factor: 79.321

4.  Dengue in the early febrile phase: viremia and antibody responses.

Authors:  D W Vaughn; S Green; S Kalayanarooj; B L Innis; S Nimmannitya; S Suntayakorn; A L Rothman; F A Ennis; A Nisalak
Journal:  J Infect Dis       Date:  1997-08       Impact factor: 5.226

5.  An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate.

Authors:  B L Innis; A Nisalak; S Nimmannitya; S Kusalerdchariya; V Chongswasdi; S Suntayakorn; P Puttisri; C H Hoke
Journal:  Am J Trop Med Hyg       Date:  1989-04       Impact factor: 2.345

6.  Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences.

Authors:  Robert V Gibbons; Siripen Kalanarooj; Richard G Jarman; Ananda Nisalak; David W Vaughn; Timothy P Endy; Mammen P Mammen; Anon Srikiatkhachorn
Journal:  Am J Trop Med Hyg       Date:  2007-11       Impact factor: 2.345

Review 7.  Prospective cohort studies of dengue viral transmission and severity of disease.

Authors:  Timothy P Endy; In-Kyu Yoon; Mammen P Mammen
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

8.  Cross-reacting antibodies enhance dengue virus infection in humans.

Authors:  Wanwisa Dejnirattisai; Amonrat Jumnainsong; Naruthai Onsirisakul; Patricia Fitton; Sirijitt Vasanawathana; Wannee Limpitikul; Chunya Puttikhunt; Carolyn Edwards; Thaneeya Duangchinda; Sunpetchuda Supasa; Kriangkrai Chawansuntati; Prida Malasit; Juthathip Mongkolsapaya; Gavin Screaton
Journal:  Science       Date:  2010-05-07       Impact factor: 47.728

9.  In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection.

Authors:  Ruklanthi de Alwis; Martina Beltramello; William B Messer; Soila Sukupolvi-Petty; Wahala M P B Wahala; Annette Kraus; Nicholas P Olivarez; Quang Pham; James D Brien; James Brian; Wen-Yang Tsai; Wei-Kung Wang; Scott Halstead; Srisakul Kliks; Michael S Diamond; Ralph Baric; Antonio Lanzavecchia; Federica Sallusto; Aravinda M de Silva
Journal:  PLoS Negl Trop Dis       Date:  2011-06-21

10.  Neutralizing antibodies after infection with dengue 1 virus.

Authors:  Maria G Guzman; Mayling Alvarez; Rosmari Rodriguez-Roche; Lidice Bernardo; Tibaire Montes; Susana Vazquez; Luis Morier; Angel Alvarez; Ernest A Gould; Gustavo Kouri; Scott B Halstead
Journal:  Emerg Infect Dis       Date:  2007-02       Impact factor: 6.883

View more
  21 in total

1.  Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.

Authors:  Peter B Gilbert; Ying Huang; Michal Juraska; Zoe Moodie; Youyi Fong; Alexander Luedtke; Yingying Zhuang; Jason Shao; Lindsay N Carpp; Nicholas Jackson; Laurent Chambonneau; Alain Bouckenooghe; Betzana Zambrano; Carina Frago; Sophie Pallardy; Fernando Noriega
Journal:  Am J Trop Med Hyg       Date:  2019-07       Impact factor: 2.345

Review 2.  Dengue: knowledge gaps, unmet needs, and research priorities.

Authors:  Leah C Katzelnick; Josefina Coloma; Eva Harris
Journal:  Lancet Infect Dis       Date:  2017-02-07       Impact factor: 25.071

Review 3.  The use of longitudinal cohorts for studies of dengue viral pathogenesis and protection.

Authors:  Leah C Katzelnick; Eva Harris
Journal:  Curr Opin Virol       Date:  2018-03-26       Impact factor: 7.090

4.  Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate.

Authors:  Jesica A Swanstrom; Sandra Henein; Jessica A Plante; Boyd L Yount; Douglas G Widman; Emily N Gallichotte; Hansi J Dean; Jorge E Osorio; Charalambos D Partidos; Aravinda M de Silva; Ralph S Baric
Journal:  J Infect Dis       Date:  2018-05-25       Impact factor: 5.226

5.  Neutralization Assay for Zika and Dengue Viruses by Use of Real-Time-PCR-Based Endpoint Assessment.

Authors:  Heather L Wilson; Thomas Tran; Julian Druce; Myrielle Dupont-Rouzeyrol; Michael Catton
Journal:  J Clin Microbiol       Date:  2017-08-09       Impact factor: 5.948

6.  Effects of Accounting for Interval-Censored Antibody Titer Decay on Seroincidence in a Longitudinal Cohort Study of Leptospirosis.

Authors:  Katharine A Owers Bonner; Jaqueline S Cruz; Gielson A Sacramento; Daiana de Oliveira; Nivison Nery; Mayara Carvalho; Federico Costa; James E Childs; Albert I Ko; Peter J Diggle
Journal:  Am J Epidemiol       Date:  2021-05-04       Impact factor: 4.897

7.  Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term.

Authors:  Leah C Katzelnick; Jose Victor Zambrana; Douglas Elizondo; Damaris Collado; Nadezna Garcia; Sonia Arguello; Juan Carlos Mercado; Tatiana Miranda; Oscarlett Ampie; Brenda Lopez Mercado; César Narvaez; Lionel Gresh; Raquel A Binder; Sergio Ojeda; Nery Sanchez; Miguel Plazaola; Krista Latta; Amy Schiller; Josefina Coloma; Fausto Bustos Carrillo; Federico Narvaez; M Elizabeth Halloran; Aubree Gordon; Guillermina Kuan; Angel Balmaseda; Eva Harris
Journal:  Sci Transl Med       Date:  2021-10-06       Impact factor: 17.956

8.  Isolation and molecular characterization of dengue virus clinical isolates from pediatric patients in New Delhi.

Authors:  Meenakshi Kar; Amul Nisheetha; Anuj Kumar; Suraj Jagtap; Jitendra Shinde; Mohit Singla; Saranya M; Awadhesh Pandit; Anmol Chandele; Sushil K Kabra; Sudhir Krishna; Rahul Roy; Rakesh Lodha; Chitra Pattabiraman; Guruprasad R Medigeshi
Journal:  Int J Infect Dis       Date:  2018-12-07       Impact factor: 3.623

9.  Immune correlates of protection for dengue: State of the art and research agenda.

Authors:  Leah C Katzelnick; Eva Harris
Journal:  Vaccine       Date:  2017-07-28       Impact factor: 3.641

10.  Using NS1 Flavivirus Protein Microarray to Infer Past Infecting Dengue Virus Serotype and Number of Past Dengue Virus Infections in Vietnamese Individuals.

Authors:  Tran Thi Nhu Thao; Erwin de Bruin; Huynh Thi Phuong; Nguyen Ha Thao Vy; Henk-Jan van den Ham; Bridget A Wills; Nguyen Thi Hanh Tien; Huynh Thi Le Duyen; Dinh The Trung; Stephen S Whitehead; Maciej F Boni; Marion Koopmans; Hannah E Clapham
Journal:  J Infect Dis       Date:  2021-06-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.